1-3 of 3
Ting-lei Gu, PhD
Close
Sort by
Journal Articles

Leukemogenic Tyrosine Kinases Inhibit PKM2 to Promote the Warburg Effect and Tumor Growth

Taro Hitosugi, PhD, Sumin Kang, PhD, Matthew Vander Heiden, MD/PhD, Tea-wook Chung, PhD, Shannon Elf, Katherine Lythgoe, Shaozhong Dong, PhD, Sagar Lonial, MD, Xu Wang, PhD, Georgia Chen, PhD, Jianxin Xie, PhD, Ting-Lei Gu, PhD, Roberto Polakiewicz, PhD, Johannes L. Roesel, PhD, Titus Boggon, PhD, Fadlo Khuri, MD, D. Gary Gilliland, MD, PhD, Lewis Cantley, PhD, Jonathan L. Kaufman, MD, Jing Chen, PhD
Journal: Blood
Blood (2010) 116 (21): 3142.
https://doi.org/10.1182/blood.V116.21.3142.3142
Published: 2010
Journal Articles

14-3-3 Integrates Pro-Survival Signals in Hematopoietic Cells Transformed by Diverse Leukemogenic Tyrosine Kinases, and Represents a Common Target.

Shaozhong Dong, PhD, Sumin Kang, PhD, Ting-lei Gu, PhD, Sean Kardar, Sagar Lonial, MD, H. Jean Khoury, MD, Fadlo Khuri, MD, Haian Fu, PhD, Jing Chen, PhD
Journal: Blood
Blood (2006) 108 (11): 1138.
https://doi.org/10.1182/blood.V108.11.1138.1138
Published: 2006
Journal Articles

FGFR3 Activates RSK2 To Mediate Hematopoietic Transformation through Both Tyrosine Phosphorylation of RSK2 and Activation of the MEK/ERK Pathway.

Sumin Kang, PhD, Shaozhong Dong, PhD, Ting-lei Gu, PhD, Michael S. Cohen, Sagar Lonial, MD, H. Jean Khoury, PhD, D. Gary Gilliland, MD, PhD, Jack Taunton, PhD, Roberto D. Polakiewicz, PhD, Jing Chen, PhD
Journal: Blood
Blood (2006) 108 (11): 514.
https://doi.org/10.1182/blood.V108.11.514.514
Published: 2006